CAJ | 학술논문

抗血小板治疗在急性冠状动脉综合征（ACS）治疗中起着关键性作用。阿司匹林联合P2Y12受体拮抗剂要氯吡格雷是冠心病患者抗血小板治疗的标准药物。新型抗血小板聚集药物替格瑞洛起效快，与血小板受体结合的可逆性，对于ACS患者的疗效及出血风险的降低十分有益。对氯吡格雷抵抗的患者仍然有效，已被多过指南列为抗血小板治疗推荐用药。替格瑞洛使抗血小板治疗迎来了新的阶段，但仍需进一步研究和观察。结合近期研究阐述替格瑞洛在急性冠状动脉综合征治疗中的应用进展。
항혈소판치료재급성관상동맥종합정（ACS）치료중기착관건성작용。아사필림연합P2Y12수체길항제요록필격뢰시관심병환자항혈소판치료적표준약물。신형항혈소판취집약물체격서락기효쾌，여혈소판수체결합적가역성，대우ACS환자적료효급출혈풍험적강저십분유익。대록필격뢰저항적환자잉연유효，이피다과지남렬위항혈소판치료추천용약。체격서락사항혈소판치료영래료신적계단，단잉수진일보연구화관찰。결합근기연구천술체격서락재급성관상동맥종합정치료중적응용진전。
In the treatment of patients with acute coronary syndrome (ACS), antiplatelet therapy plays a key role, the standard drug of which was aspirin combined with P2Y12 receptor antagonist clopidogrel. However, a new type of anti-platelet aggregation drug, ticagrelor which has reversibility in platelet receptor binding shows fast onset in the treatment of patients with ACS and good effect in reducing bleeding risk. What is more, it is effective in treating patients with clopidogrel resistance, therefore, it has been recommended in many guidelines. Further research should be done although it has led the antiplatelet therapy into a new phase. This paper reviews the research progress on ticagrelor in the treatment of ACS based on the research studies.